ES3058737T3 - Treatment of left ventricular remodeling - Google Patents

Treatment of left ventricular remodeling

Info

Publication number
ES3058737T3
ES3058737T3 ES24159638T ES24159638T ES3058737T3 ES 3058737 T3 ES3058737 T3 ES 3058737T3 ES 24159638 T ES24159638 T ES 24159638T ES 24159638 T ES24159638 T ES 24159638T ES 3058737 T3 ES3058737 T3 ES 3058737T3
Authority
ES
Spain
Prior art keywords
approximately
heart failure
levels
dmt
phe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES24159638T
Other languages
English (en)
Spanish (es)
Inventor
Travis D Wilson
Hani N Sabbah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henry Ford Health System
Stealth Biotherapeutics Inc
Original Assignee
Henry Ford Health System
Stealth Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henry Ford Health System, Stealth Biotherapeutics Inc filed Critical Henry Ford Health System
Application granted granted Critical
Publication of ES3058737T3 publication Critical patent/ES3058737T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Emergency Medicine (AREA)
ES24159638T 2012-10-22 2013-10-22 Treatment of left ventricular remodeling Active ES3058737T3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261716867P 2012-10-22 2012-10-22
US201361822752P 2013-05-13 2013-05-13
US201361839743P 2013-06-26 2013-06-26
US201361839750P 2013-06-26 2013-06-26

Publications (1)

Publication Number Publication Date
ES3058737T3 true ES3058737T3 (en) 2026-03-12

Family

ID=50545459

Family Applications (1)

Application Number Title Priority Date Filing Date
ES24159638T Active ES3058737T3 (en) 2012-10-22 2013-10-22 Treatment of left ventricular remodeling

Country Status (13)

Country Link
US (4) US20150246092A1 (enExample)
EP (5) EP4397314B1 (enExample)
JP (3) JP2016503397A (enExample)
KR (1) KR20160009008A (enExample)
CN (2) CN110193077A (enExample)
AU (2) AU2013334788A1 (enExample)
BR (1) BR112015009072A2 (enExample)
CA (1) CA2889155A1 (enExample)
ES (1) ES3058737T3 (enExample)
MX (1) MX2015005102A (enExample)
NI (1) NI201500057A (enExample)
PE (1) PE20151434A1 (enExample)
WO (1) WO2014066419A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3626252A1 (en) 2013-03-01 2020-03-25 Stealth Biotherapeutics Corp Methods and compositions for the prevention or treatment of barth syndrome
US10793597B2 (en) 2013-03-01 2020-10-06 Stealth Biotherapeutics Corp Methods for the treatment of mitochondrial diseases associated with a mutation in SURF 1 or POLG gene resulting in a disruption of mitochondrial oxidative phosphorylation
US10047395B2 (en) * 2013-06-26 2018-08-14 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
US10870678B2 (en) 2016-04-11 2020-12-22 Arcuate Therapeutics, Inc. Chiral peptides
EP3474877A4 (en) * 2016-06-24 2019-11-27 University of Southern California MENTSH ANALOGUE AS THERAPEUTICS FOR DIABETES, ADIPOSITAS AND ASSOCIATED DISEASES AND COMPLICATIONS THEREOF
JP7630906B2 (ja) 2017-02-01 2025-02-18 イェール・ユニヴァーシティー 利尿薬耐性の治療
SG11202006157VA (en) 2018-01-05 2020-07-29 Corvidia Therapeutics Inc Methods for treating il-6 mediated inflammation without immunosuppression
KR102546547B1 (ko) 2018-01-11 2023-06-22 삼성전자주식회사 보행 보조 방법 및 장치
KR20220052561A (ko) 2020-10-21 2022-04-28 장영진 어류 가공물 및/또는 콩 가공물을 유효성분으로 포함하는 심부전의 예방 또는 치료용 약학 조성물
CN120329388B (zh) * 2025-04-30 2025-09-26 中日友好医院(中日友好临床医学研究所) 一种双靶点多肽及其在心衰治疗中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US20040131614A1 (en) * 2002-07-19 2004-07-08 Abbott Biotechnology Ltd. Treatment of pulmonary disorders using TNFalpha inhibitor
SI2656854T1 (sl) * 2003-02-04 2015-09-30 Cornell Research Foundation, Inc. Uporabe aromatsko-kationskega peptida
EP1890153A1 (en) * 2006-08-16 2008-02-20 F. Hoffman-la Roche AG Cardiac troponin as an indicator of advanced coronary artery disease
EP1890154B1 (en) * 2006-08-16 2012-07-04 F. Hoffmann-La Roche AG Cardiac troponin as an indicator of advanced coronary artery disease
US20080318909A1 (en) * 2007-06-14 2008-12-25 Sparagna Genevieve C Use Of Linoleic Compounds Against Heart Failure
CN107802821A (zh) * 2008-02-26 2018-03-16 康奈尔大学 用于防止和治疗急性肾损伤的方法
CA2770688C (en) * 2009-08-12 2018-06-05 Cornell University Methods for preventing or treating metabolic syndrome
EP3603658B1 (en) * 2009-10-05 2025-01-08 Cornell University Peptide for use in the treatment of heart failure resulting from hypertrophic cardiomyopathy
EP2504032A4 (en) * 2009-11-24 2013-06-19 Alderbio Holdings Llc IL-6 ANTAGONISTS FOR PREVENTING OR TREATING THROMBOSIS
EP2519249A4 (en) * 2009-12-31 2013-06-26 Stealth Peptides Int Inc METHOD FOR CARRYING OUT A CORONARY ARTERY BYPASS PROCEDURE
US20130195837A1 (en) * 2009-12-31 2013-08-01 Stealth Peptides International, Inc. Methods for the prevention or treatment of vessel occlusion injury
EP3332795A1 (en) * 2010-02-26 2018-06-13 Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
EP2808029A3 (en) * 2010-03-15 2015-04-01 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
US10188693B2 (en) * 2012-08-02 2019-01-29 Stealth Biotherapeutics Corp Methods for treatment of atherosclerosis
HK1215934A1 (zh) * 2012-12-06 2016-09-30 Stealth Peptides International, Inc. 肽治疗剂及其使用方法
CA2916497C (en) * 2013-06-26 2022-07-12 Stealth Biotherapeutics Corp Methods for the regulation of matrix metalloproteinase expression
US10047395B2 (en) * 2013-06-26 2018-08-14 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions

Also Published As

Publication number Publication date
JP2016503397A (ja) 2016-02-04
EP4397314B1 (en) 2025-12-03
US20230190859A1 (en) 2023-06-22
KR20160009008A (ko) 2016-01-25
HK1213799A1 (en) 2016-07-15
NI201500057A (es) 2015-07-16
EP4397314A1 (en) 2024-07-10
JP2018109012A (ja) 2018-07-12
US20150246092A1 (en) 2015-09-03
CA2889155A1 (en) 2014-05-01
US20200360462A1 (en) 2020-11-19
EP3586862A1 (en) 2020-01-01
EP3586862B1 (en) 2021-12-08
EP4005582A1 (en) 2022-06-01
US20250255929A1 (en) 2025-08-14
CN110193077A (zh) 2019-09-03
EP2908839A2 (en) 2015-08-26
EP4711005A3 (en) 2026-04-22
MX2015005102A (es) 2016-02-09
EP2908839A4 (en) 2016-06-15
WO2014066419A2 (en) 2014-05-01
AU2013334788A1 (en) 2015-06-04
WO2014066419A3 (en) 2014-06-12
PE20151434A1 (es) 2015-10-16
EP4711005A2 (en) 2026-03-18
AU2018206766A1 (en) 2018-08-09
CN105050613A (zh) 2015-11-11
JP2019194193A (ja) 2019-11-07
EP2908839B1 (en) 2019-08-21
BR112015009072A2 (pt) 2017-07-04

Similar Documents

Publication Publication Date Title
US20230190859A1 (en) Methods for reducing risks associated with heart failure and factors associated therewith
ES2236415T3 (es) Inhibicion de la histona desacetilasa para el tratamiento de la hipertrofia cardiaca.
Mourouzis et al. Thyroid hormone improves the mechanical performance of the post-infarcted diabetic myocardium: a response associated with up-regulation of Akt/mTOR and AMPK activation
JP7381652B2 (ja) バース症候群の予防または治療のための方法及び組成物
ES2755183T3 (es) Compuestos ppar para uso en el tratamiento de enfermedades fibróticas
ES2864168T3 (es) Cilastatina para su uso en el tratamiento de la sepsis
Zeng et al. Impairment of Cardiac Function and Remodeling Induced by Myocardial Infarction in Rats are Attenuated by the Nonpeptide Angiotensin‐(1–7) Analog AVE 0991
JP2019052157A (ja) 左室リモデリングの予防または治療のための方法
KR20150048663A (ko) 패혈증 치료를 위한 티모신 알파의 용도
HK40115529B (en) Treatment of left ventricular remodeling
US20240197817A1 (en) Compositions for treating autoimmune, alloimmune, inflammatory, and mitochondrial conditions, and uses thereof
US12409206B2 (en) Use of cyclosporine analogues for treating fibrosis
HK40115529A (en) Treatment of left ventricular remodeling
ES2961003T3 (es) D-Arg-2'6'-Dmt-Lys-Phe-NH2 para su uso en el tratamiento o la prevención del síndrome de Sengers
HK1213799B (en) Methods for reducing risks associated with heart failure and factors associated therewith
Breault Preclinical Investigation of Mitochondrial Fission Inhibitors in Pulmonary Arterial Hypertension and Non-Small Cell Lung Cancer
HK40061712B (en) D-arg-2'6'-dmt-lys-phe-nh2 for use in treating or preventing sengers syndrome
Gupta Metalloprotease and endothelin-mediated signaling mechanisms in sepsis and related cardiovascular disorders